We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

160 hedge funds and large institutions have $1.78B invested in Syndax Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

28% more capital invested

Capital invested by funds: $1.39B → $1.78B (+$393M)

15% more funds holding

Funds holding: 139 → 160 (+21)

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

8% more call options, than puts

Call options by funds: $2.77M | Put options by funds: $2.56M

0.59% more ownership

Funds ownership: 105.87% → 106.47% (+0.59%)

Holders
160
Holders Change
+21
Holders Change %
+15.11%
% of All Funds
2.57%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.18%
New
32
Increased
65
Reduced
41
Closed
10
Calls
$2.77M
Puts
$2.56M
Net Calls
+$203K
Net Calls Change
-$4.79M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$83.9M
2
State Street
State Street
Massachusetts
+$24M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$21.5M
4
PBA
Paradigm Biocapital Advisors
New York
+$20.3M
5
Barclays
Barclays
United Kingdom
+$16M

Top Sellers

1
WP
Woodline Partners
California
-$19M
2
HM
HealthCor Management
New York
-$18.4M
3
6CM
683 Capital Management
New York
-$13.1M
4
NCM
Nantahala Capital Management
Connecticut
-$9.32M
5
BI
BVF Inc
California
-$8.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
QCG
151
Quadrant Capital Group
Ohio
$3.26K – – –
PNC Financial Services Group
152
PNC Financial Services Group
Pennsylvania
$2.49K – – –
LC
153
Lindbrook Capital
California
$2.42K -$3.83K -164 -63%
Rockefeller Capital Management
154
Rockefeller Capital Management
New York
$2K – – –
S
155
SignatureFD
Georgia
$1.78K – – –
AF
156
Allworth Financial
California
$1.68K +$723 +31 +89%
BAAM
157
Baker Avenue Asset Management
California
$1.6K +$1.47K +63 New
MPWT
158
MassMutual Private Wealth & Trust
Connecticut
$1K – – –
Nisa Investment Advisors
159
Nisa Investment Advisors
Missouri
$1K – – –
WP
160
Woodline Partners
California
– -$19M -789,273 Closed
Ameriprise
161
Ameriprise
Minnesota
– -$6.65M -276,731 Closed
BBA
162
Baker Bros. Advisors
New York
– -$2.66M -110,729 Closed
ECM
163
ExodusPoint Capital Management
New York
– -$1.41M -58,466 Closed
CANY
164
Caxton Associates (New York)
New York
– -$615K -25,576 Closed
Voloridge Investment Management
165
Voloridge Investment Management
Florida
– -$518K -21,563 Closed
Verition Fund Management
166
Verition Fund Management
Connecticut
– -$258K -10,737 Closed
SOW
167
State of Wyoming
Wyoming
– -$30K -1,234 Closed
QC
168
Quent Capital
New York
– -$1K -59 Closed
C
169
Covestor
United Kingdom
– -$23 -1 -7%
3 4 5 6
7

SNDX Hedge Fund Activity: Q4 2022 in Review

160 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2022, worth a combined $1.78B — up 28% from $1.39B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SNDX positions and 10 closed out — a net gain of 22 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $83.9M. The largest seller was Woodline Partners, exiting entirely with an estimated $19M sold.

  • 160 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2022, up from 139 in Q3 2022.
  • Funds reported $1.78B of Syndax Pharmaceuticals stock for Q4 2022, up 28% quarter-over-quarter.
  • 32 funds opened new Syndax Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of +22 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2022 was Wellington Management Group, an estimated $83.9M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2022 was Woodline Partners, an estimated $19M sold.

Based on aggregated 13F filings for Q4 2022.